Alisertib (MLN8237)

Name: Alisertib (MLN8237)
Brand: Selleck Chemicals
SKU: S1133
Rating: 5 (268 reviews)

For research use only.

Catalog No.S1133

268 publications

CAS No. 1028486-01-2

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Selleck's Alisertib (MLN8237) has been cited by 268 publications

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00338-X

PubMed: 34270926 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4789

PubMed: 34373451 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5203

PubMed: 34471141 ( click the link to review the publication )

EMBO Rep, 2021, e51902

PubMed: 34169630 ( click the link to review the publication )

Cancer Res, 2021, canres.2811.2020

PubMed: 34247147 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):821

PubMed: 34462431 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

PLoS Genet, 2021, 17(4):e1009327

PubMed: 33901174 ( click the link to review the publication )

Neoplasia, 2021, 23(6):624-633

PubMed: 34107377 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(6):3240-3251

PubMed: 34249458 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

Mol Pharmacol, 2021, 99(6):435-447

PubMed: 33795352 ( click the link to review the publication )
J Nat Prod, 2021, 84(8):2312-2320

PubMed: 34406008 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12125

PubMed: 33471959 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12190

PubMed: 34251762 ( click the link to review the publication )

Mol Cell Endocrinol, 2021, 528:111243

PubMed: 33716050 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01019-9

PubMed: 33409897 ( click the link to review the publication )

Biomed Res Int, 2021, 2021:6613439

PubMed: 34337035 ( click the link to review the publication )

Int J Med Sci, 2021, 18(15):3437-3451

PubMed: 34522170 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2616

PubMed: 33510346 ( click the link to review the publication )

EMBO Rep, 2021, e51030

PubMed: 33615693 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancer Lett, 2020, 495:135-144

PubMed: 32979462 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3406-3414

PubMed: 33163279 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.1226.2019

PubMed: 32591441 ( click the link to review the publication )

Front Oncol, 2020, 10:1354

PubMed: 32974133 ( click the link to review the publication )

J Cell Sci, 2020, 133(24)jcs240267

PubMed: 33376154 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44289

PubMed: 32571902 ( click the link to review the publication )
J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6690

PubMed: 32932728 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3424-3435

PubMed: 32595135 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:857

PubMed: 33042987 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

CU Digital Repository, 2020, N/A

PubMed: N/A ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa570

PubMed: 32652013 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )
Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )

FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(3):312-323

PubMed: 30485161 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Int J Oncol, 2019, 55(4):938-948

PubMed: 31485600 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Oncogene, 2019, 38(40):6696-6710

PubMed: 31391550 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

J Vis Exp, 2019, (151)

PubMed: 31589210 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

J Cell Biol, 2018, 217(1):107-116

PubMed: 29074706 ( click the link to review the publication )

J Cell Biol, 2018, 217(2):483-493

PubMed: 29222185 ( click the link to review the publication )
Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

BMC Biol, 2018, 16(1):116

PubMed: 30336771 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Pharmacol Res, 2018, 134:166-178

PubMed: 29944980 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )
Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )

R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 27593935 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

J Cell Sci, 2017, 130(4):683-688

PubMed: 28069833 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )
J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )
Elife, 2016, 5:e10877

PubMed: 26880562 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Cell Biochem, 2016, 117(6):1340-51

PubMed: 26529125 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58435-58444

PubMed: 27533080 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

J Cell Biol, 2015, 210(1):45-62

PubMed: 26124292 ( click the link to review the publication )
Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015,

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Cell Cycle, 2015, 14(9):1447-58

PubMed: 25789545 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )
Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2013, 110(19):E1779-87

PubMed: 23610398 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

J Cell Biol, 2013, 202(3):463-78

PubMed: 23918938 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

Oncotarget, 2011,

PubMed: 21865609 ( click the link to review the publication )
J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Features

First orally available inhibitor of Aurora A.

Targets

Aurora A ^[1]
(Cell-free assay)

1.2 nM

In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. ^[1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. ^[2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPaNXN1OC53IN88US=>	M{fJPFczKGh?	NUDCVZpQTE2VTx?=	M{XKVmlEPTB;MD6wOEDPxE1?	NVLlNFJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
LS174T	MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXtcXZDOC53IN88US=>	M2\zeVczKGh?	Mn3rSG1UVw>?	NY\zPWw4UUN3ME2wMlA2KM7:TR?=	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
T84	NFrzNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\xNYUxNjVizszN	MY[3NkBp	MYjEUXNQ	M3HIXmlEPTB;MD6wPUDPxE1?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
LS180	M2jiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\xV2pEOC53IN88US=>	NGP3SZk4OiCq	NWDo[lFJTE2VTx?=	NYfCb3FyUUN3ME2xJO69VQ>?	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
SW948	NXXad5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXewMlUh\|ryP	Mn7YO\|IhcA>?	M{XMZ2ROW09?	M{TwXWlEPTB;MTFOwG0>	M3nOelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
HCT15	NGTx[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXNR4MxNjVizszN	MmK4O\|IhcA>?	M{[0S2ROW09?	MnqzTWM2ODxyLkSg{txO	NFPRU\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
DLD-1	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fETFAvPSEQvF2=	MVG3NkBp	MmLzSG1UVw>?	M3rRdGlEPTB:MD64JO69VQ>?	NHuxPXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
MIP-101	NVfmW5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHYc4QxNjVizszN	MVy3NkBp	M3\BNWROW09?	M{nZO2lEPTB;MTFOwG0>	NIPuNG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
SNU1544	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLCO2sxNjVizszN	MWK3NkBp	NXn3ZpptTE2VTx?=	NH3yZohKSzVyPUGg{txO	NYqweFBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
OCI-Ly10	NYDXT3A2S3m2b4TvfIlkKEG\|c3H5		NFX4fJQ4OiCq	MYLEUXNQ	M3jVcWlEPTB;MD6wOVgh\|ryP	M{\JN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
SU-DHL2	NIfJdolEgXSxdH;4bYMhSXO\|YYm=		NFzVe2Q4OiCq	MVfEUXNQ	M2L6XGlEPTB;MD6wNUDPxE1?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
OCI-LY7	MXnDfZRwfG:6aXOgRZN{[Xl?		NEOyNmU4OiCq	NIDl[nhFVVOR	MlPmTWM2OD1yLkC4NUDPxE1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
SU-DHL6	MXvDfZRwfG:6aXOgRZN{[Xl?		M2qxRVczKGh?	M33nN2ROW09?	NG\PdVlKSzVyPUCuOFgzKM7:TR?=	NUD2ZlhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
Jeko-1	M3jVWWN6fG:2b4jpZ{BCe3OjeR?=		NVzYelRUPzJiaB?=	M3;DbWROW09?	NEHuNlZKSzVyPUCuNFI6KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
JVM-2	NGXqVIxEgXSxdH;4bYMhSXO\|YYm=		NF\pepE4OiCq	MYfEUXNQ	MoW1TWM2OD1yLkCxJO69VQ>?	M2DEOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
Rec-1	NFP6eVlEgXSxdH;4bYMhSXO\|YYm=		NXvsW285PzJiaB?=	NXXLUoE3TE2VTx?=	NVLkcJZTUUN3ME2wMlA5PyEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Z-138	NGrMPIZEgXSxdH;4bYMhSXO\|YYm=		M1HyVVczKGh?	NUPZfFJDTE2VTx?=	M3\GZmlEPTB;MD6wNVMh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
H9	MnS0R5l1d3SxeHnjJGF{e2G7		NXzTXW1oPzJiaB?=	NFrkbGxFVVOR	MVPJR\|UxRTBwNjFOwG0>	NV;oPWJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
HH	M3\L[GN6fG:2b4jpZ{BCe3OjeR?=		M3XqPFczKGh?	MoixSG1UVw>?	NXXVWVdYUUN3ME2wMlch\|ryP	NWq1Z2VjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
DND41	MWfDfZRwfG:6aXOgRZN{[Xl?		NEnXcpI4OiCq	MWjEUXNQ	NGPyOZdKSzVyPUCuNUDPxE1?	MknSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
CCL119	MlXJR5l1d3SxeHnjJGF{e2G7		MWW3NkBp	MojsSG1UVw>?	NVf3[JZ5UUN3ME2wMlA3OiEQvF2=	NU\iU\|B7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
J.Cam 1.6	M3zSNmN6fG:2b4jpZ{BCe3OjeR?=		NEDLT4M4OiCq	MnyxSG1UVw>?	NUPqV25uUUN3ME2wMlExPSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Sup-T1	MnLXR5l1d3SxeHnjJGF{e2G7		NH:4eow4OiCq	Mk\VSG1UVw>?	M4G2dGlEPTB;Mj6xOFIh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Tib 152	MoD5R5l1d3SxeHnjJGF{e2G7		NGjiXYE4OiCq	MnjTSG1UVw>?	MmTTTWM2OD1yLkig{txO	M4TpdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
MCF7	NWjKSItuTnWwY4Tpc44hSXO\|YYm=	MX:1JO69VQ>?	MmiwNlQhcA>?	M4\U[GROW09?	MV7JcoR2[2W\|IFeyM20h[XK{ZYP0	MknnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	M4\LWWZ2dmO2aX;uJGF{e2G7	MYG1JO69VQ>?	MYqyOEBp	NXPLdGhFTE2VTx?=	MlPJTY5lfWOnczDHN{9OKGG{cnXzeC=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	NHrlTGFHfW6ldHnvckBCe3OjeR?=	M3\xOFUh\|ryP	MorCNlQhcA>?	M{jQfmROW09?	M2PsbGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K=	MoDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	NEXNUlhHfW6ldHnvckBCe3OjeR?=	MXK1JO69VQ>?	NUS4XG5COjRiaB?=	M33CSmROW09?	NUHWbWY2TGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzJ?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	Mlf1SpVv[3Srb36gRZN{[Xl?	MlPQOUDPxE1?	MUWyOEBp	NHrVOWxFVVOR	NFztbFdF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx	NGTsO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	Mmn6SpVv[3Srb36gRZN{[Xl?	Mlu3OUDPxE1?	Mkf3NlQhcA>?	MV\EUXNQ	MV;JcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=>	M13HdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MCF7	M17qPWZ2dmO2aX;uJGF{e2G7	NH[0TWo2KM7:TR?=	M3nRTVI1KGh?	NVTBWW5LTE2VTx?=	MXLJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF?	M3\Ye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	NIL0O3lHfW6ldHnvckBCe3OjeR?=	NGLEUlI2KM7:TR?=	M1nBRlI1KGh?	M2HrSWROW09?	NFPxfpJF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy	MnzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	NXTINldjTnWwY4Tpc44hSXO\|YYm=	MkWzNUDPxE1?	NFyyZ2UzPCCq	NGrEUZFFVVOR	MoXKTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET\|I>	NWe4U5N2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	MlXWSpVv[3Srb36gRZN{[Xl?	MX:1JO69VQ>?	MnH5NlQhcA>?	Mn7aSG1UVw>?	MWnE[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz	M3jvfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	NFrUfWpHfW6ldHnvckBCe3OjeR?=	MW[1JO69VQ>?	MkXNNlQhcA>?	MX3EUXNQ	NVnubpRQUW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF?	NXvqdFQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	M{XZS2Z2dmO2aX;uJGF{e2G7	MmPIOUDPxE1?	M4TwfFI1KGh?	NVrkVZh2TE2VTx?=	MYjJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	NEDKSFlHfW6ldHnvckBCe3OjeR?=	NU\6Tm1SPSEQvF2=	NVO0W2F[OjRiaB?=	NHy4[GNFVVOR	M3znWGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwOVM>	NF3vWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	NVHnXI9YSXCxcITvd4l{KEG\|c3H5	M1nxcVUh\|ryP	NEHKXmczPCCq	M3HoVGROW09?	MX\JcoR2[2W\|IHHwc5B1d3SrYzDk[YF1cA>?	MlP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	M{XjWGFxd3C2b4Ppd{BCe3OjeR?=	M2DMRlUh\|ryP	MVuyOEBp	NWTaN5NrTE2VTx?=	NGPKNHBKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	NH3NXmxHfW6ldHnvckBCe3OjeR?=	MmS2NUDPxE1?	MUS3NkBp	M3nkbmROW09?	MmnNTY5lfWOnczDheZRweGijZ3njJIRm[XSq	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MmrISpVv[3Srb36gRZN{[Xl?	NYjJUZNkOSEQvF2=	MVe3NkBp	MmjJSG1UVw>?	NUXxNmhtUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
U-2 OS	NI[wUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXlOVAh\|ryP	MnXNNlQhcA>?	NYD0OWxzTE2VTx?=	MnTSTWM2OD1zNj62JO69VQ>?	NHfHTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
MG-63	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDaO3ZYPTBizszN	NG\EUmUzPCCq	Ml\DSG1UVw>?	M3HQRmlEPTB;OT61JO69VQ>?	NXqzellZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
U-2 OS	MWHBdI9xfG:\|aYOgRZN{[Xl?	Mn;2OUDPxE1?	Ml\nNlQhcA>?	NEPDe\|VFVVOR	NFPoXohKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp	NUXUV5NsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	M4nFTmFxd3C2b4Ppd{BCe3OjeR?=	M4nEflUh\|ryP	NG\JbpYzPCCq	NYLKdI9oTE2VTx?=	NVS2c\|R2UW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	NXLuS25bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
U-2 OS	M{G5[GZ2dmO2aX;uJGF{e2G7	NUXCcmg6PSEQvF2=	MYqyOEBp	M3r3TmROW09?	M1G4N3Bzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	M4LublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
MG-63	Mn7KSpVv[3Srb36gRZN{[Xl?	M{jsXVUh\|ryP	M2PPVVI1KGh?	NWT4e3ZmTE2VTx?=	MWLQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg>	NG\UN4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
PANC-1	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYC1NEDPxE1?	MmXPNlQhcA>?	NHnHT2pFVVOR	M1jTNWlEPTB;Nz6xJO69VQ>?	NFnET2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
BxPC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWe1NEDPxE1?	MWSyOEBp	M4TJfWROW09?	MW\JR\|UxRTZwODFOwG0>	NF\LPHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
PANC-1	NIf2VG1HfW6ldHnvckBCe3OjeR?=	NF\sNnc2KM7:TR?=	NH;RXJozPCCq	MnP0SG1UVw>?	NXzsZZBkUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn	M2HHT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
BxPC-3	NV;VWI0{TnWwY4Tpc44hSXO\|YYm=	M3\PSlUh\|ryP	M1jwUlI1KGh?	NGrhelFFVVOR	MWnJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U>	Mnj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{KyNlUoRjJ3NkOyNlI2RC:jPh?=
PANC-1	M33PSWZ2dmO2aX;uJGF{e2G7	Mn:1OUDPxE1?	MmPJNlQhcA>?	M2D6ZWROW09?	MmHzTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg>	NX;yZ\|NGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
BxPC-3	NUS2dnFFTnWwY4Tpc44hSXO\|YYm=	MoXOOUDPxE1?	MmHRNlQhcA>?	MlPoSG1UVw>?	MXfJcoR2[2W\|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=>	M4DtdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
SKOV3	NWLwdWRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\oNVAxKM7:TR?=	MVGyOEBp	MoPJSG1UVw>?	M1HaeGlEPTB;MkCuOFgh\|ryP	MmDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
OVCAR4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrtRXkxOTByIN88US=>	NHqyZXEzPCCq	MnntSG1UVw>?	M1jnS2lEPTB;MkKuNVMh\|ryP	MonhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
SKOV3	MWDGeY5kfGmxbjDBd5NigQ>?	MYG1JO69VQ>?	NI\wRYU4OiCq	NE[wWXNFVVOR	NVfuUY14UW6mdXPld{BIOi:PIHHydoV{fA>?	MkjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
OVCAR4	M{\EVGZ2dmO2aX;uJGF{e2G7	NETkTWY2KM7:TR?=	MVi3NkBp	NHXKSYVFVVOR	M3nDSWlv\HWlZYOgS\|IwVSCjcoLld5Q>	NYq5[mRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
SKOV3	MkfjRZBweHSxc3nzJGF{e2G7	NGPXdlM2KM7:TR?=	NV;KOXo4OjRiaB?=	M{PjfGROW09?	M13sTWlv\HWlZYOgZZBweHSxc3nz	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	MmPoRZBweHSxc3nzJGF{e2G7	Mmi0OUDPxE1?	NFztO5kzPCCq	MkTiSG1UVw>?	M2HTfWlv\HWlZYOgZZBweHSxc3nz	MnzZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
AGS	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzvNlUh\|ryP	NFHTZ4UzPCCq	M1y5V2ROW09?	MXXJR\|UxRTF7LkC5JO69VQ>?	NX30dGx[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
NCI-N78	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zrUlI2KM7:TR?=	M4HtU\|I1KGh?	MnvjSG1UVw>?	NUfpd3lGUUN3ME2yOk4{OyEQvF2=	MnPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MEm5NlMoRjJ3NkC5PVI{RC:jPh?=
AGS	MXXBdI9xfG:\|aYOgRZN{[Xl?	M3mx[\|Uh\|ryP	NVv6SG5SOjRiaB?=	M{nmZWROW09?	NVXr[Ip6UW6mdXPld{BieG:ydH;zbZM>	M4nyZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
NCI-N78	MlPYRZBweHSxc3nzJGF{e2G7	M1X4dFUh\|ryP	M2\HTFI1KGh?	NYXmN4ViTE2VTx?=	NEPldW5KdmS3Y3XzJIFxd3C2b4Ppdy=>	M1nlTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
AGS	M3uzXWZ2dmO2aX;uJGF{e2G7	MnzrOUDPxE1?	MnK4NlQhcA>?	MYrEUXNQ	M12zc2lv\HWlZYOgeIhmKGG3dH;wbIFogQ>?	NY\PVms6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
NCI-N78	NYnyN4JQTnWwY4Tpc44hSXO\|YYm=	M2jCUlUh\|ryP	NHf6e3QzPCCq	NVL5bWg3TE2VTx?=	NUGwXohEUW6mdXPld{B1cGViYYX0c5Bp[We7	NUXze45ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
HSC-3	M3HCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYexJO69VQ>?	NYC5XnRiPDhiaB?=		MkD0TWM2OD1yLkW0JO69VQ>?	NE\QRmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2OlE1Oyd-MkWzOlYyPDN:L3G+
GB30	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:5NUDPxE1?	MXS3JIQ>	MWrEUXNQ	M{HmfmlEPTB;MD6wNVEh\|ryP	MlLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzME[0NlgoRjJ3MUC2OFI5RC:jPh?=
GB9	NHfpcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jFe\|Eh\|ryP	M4j3c\|ch\A>?	NXrJTohJTE2VTx?=	M3TRT2lEPTB;MD6wNlQh\|ryP	NXzTVXBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFY1OjhpPkK1NVA3PDJ6PD;hQi=>
GB169	NGfFdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVyxJO69VQ>?	M361elch\A>?	M3vhbmROW09?	MnTrTWM2OD1yLkCzNkDPxE1?	NE\URpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOlQzQCd-MkWxNFY1Ojh:L3G+
T24	M163bWZ2dmO2aX;uJGF{e2G7	MV2xJO69VQ>?	MkfaOFghcA>?	MWrEUXNQ	M33PUGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NF32dmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
RT4	M3niTmZ2dmO2aX;uJGF{e2G7	NE[xNXAyKM7:TR?=	MoPNOFghcA>?	MkLiSG1UVw>?	NXjpS\|JMUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	NIrN[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
UM-UC-3	NEThdGxHfW6ldHnvckBCe3OjeR?=	M4CwXlEh\|ryP	MXm0PEBp	NESwWYxFVVOR	MoO5TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dB?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
T24	NVqxZ4FISXCxcITvd4l{KEG\|c3H5	NEjsWY4{NjF4IN88US=>	MX25OkBp	MUfEUXNQ	MYnJR\|UxRTBwMEOwOkDPxE1?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
RT4	M3P1RmFxd3C2b4Ppd{BCe3OjeR?=	NWLFVXdMOy5zNjFOwG0>	MV65OkBp	M33BbGROW09?	NYXjfXNbUUN3ME2wMlEyQThizszN	MoXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N\|MoRjJ\|NECzOlM{RC:jPh?=
UM-UC-3	NVHCT2F[SXCxcITvd4l{KEG\|c3H5	M1;B[\|MvOTZizszN	M1\yTFk3KGh?	NWSwd\|N1TE2VTx?=	M3nQ[GlEPTB;MD6wOFQ6KM7:TR?=	MmrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N\|MoRjJ\|NECzOlM{RC:jPh?=
OVCAR-5	Ml\tSpVv[3Srb36gRZN{[Xl?	NFTjRoQ2OCCwTR?=			NEnq[VlKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?=	MlyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|M{SzNlcoRjJ\|M{O0N\|I4RC:jPh?=
SKOV3ip2	MUTGeY5kfGmxbjDBd5NigQ>?	M3;wdlUxKG6P			NVLBPYo2UW6qaXLpeJMh[2WubDDtbYdz[XSrb36=	M1[xeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{O0N\|I4Lz5{M{OzOFMzPzxxYU6=
S462	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoX5NVAxKM7:TR?=	MVu3NkBp	NX\QVHJvTE2VTx?=	NHzaPG5CfHSnboXheIV{KGOnbHyg[5Jwf3Sq	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEGxOEc,OjN\|MkixNVQ9N2F-
2884	NWDWT\|g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XTOVExOCEQvF2=	MmnHO\|IhcA>?	M1\nR2ROW09?	M3zwVGF1fGWwdXH0[ZMh[2WubDDndo94fGh?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEGxOEc,OjN\|MkixNVQ9N2F-
2885	NGDIOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37GWFExOCEQvF2=	NG\vSpE4OiCq	MUTEUXNQ	MlT4RZR1\W63YYTld{Bk\WyuIHfyc5d1cA>?	M4H1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
CRL-2396	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M364O\|ExOCEQvF2=		NFvXdoN4[XSnch?=	NVzOb\|JwUUN3ME2wMlA6OiEQvF2=	NWTIdppqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOVM2OjRpPkKzNVU{PTJ2PD;hQi=>
TIB-48	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTqXpdkOTByIN88US=>		MY\3ZZRmeg>?	M2jrc2lEPTB;MD6wPFgh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF3M{WyOEc,OjNzNUO1NlQ9N2F-
CRL-2396	MUDDfZRwfG:6aXOgRZN{[Xl?	NWjKOHFiOSEQvF2=	NEPwVGM1QCCq	NYf1OlVVf2G2ZYK=	NGXxb4JKdmS3Y3XzJIFxd3C2b4Ppdy=>	M{LiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWzOVI1Lz5{M{G1N\|UzPDxxYU6=
TIB-48	MXjDfZRwfG:6aXOgRZN{[Xl?	NFvx[WcyKM7:TR?=	Mo\jOFghcA>?	MXT3ZZRmeg>?	NVn6PGRTUW6mdXPld{BieG:ydH;zbZM>	MlT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUO1NlQoRjJ\|MUWzOVI1RC:jPh?=
AGS	MnznR5l1d3SxeHnjJGF{e2G7	MnT4NE42KM7:TR?=	NWCyV5MyOjRiaB?=	NEPIdWZFVVOR	MnzISIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	NF7nSmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm3NlYyOSd-MkK5O\|I3OTF:L3G+
FLO-1	MYTDfZRwfG:6aXOgRZN{[Xl?	NXPTXlM2OC53IN88US=>	NGnzPHEzPCCq	M2TvfGROW09?	NHnpemFF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl5Mk[xNUc,OjJ7N{K2NVE9N2F-
OE33	NEHGVnVEgXSxdH;4bYMhSXO\|YYm=	MWqwMlUh\|ryP	MmLMNlQhcA>?	NGf1SJZFVVOR	Ml;mSIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl5Mk[xNUc,OjJ7N{K2NVE9N2F-
SKLMS	MXfDfZRwfG:6aXOgRZN{[Xl?	NYjkUXhqPzVibl2=	MWS5OkBp		MoqzTY5lfWOnczDhdI9xfG:\|aYO=	M3P4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEKxPVk4Lz5{MkiyNVk6PzxxYU6=
Leio285	Ml\oR5l1d3SxeHnjJGF{e2G7	Mlv5O\|Uhdk1?	M1OxVFk3KGh?		MoDlTY5lfWOnczDhdI9xfG:\|aYO=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
Mes-Sa	MmDWR5l1d3SxeHnjJGF{e2G7	MoXRO\|Uhdk1?	M1WyVFk3KGh?		NYLZNnRjUW6mdXPld{BieG:ydH;zbZM>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
DAOY	MU\DfZRwfG:6aXOgRZN{[Xl?	Mo\yNVAh\|ryP	NX;N[GZmPzJiaB?=	NYHxdYcxTE2VTx?=	MkfBTWM2OD1yLkC0JO69VQ>?	NHrWVJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[2PVM{PSd-MkK2Olk{OzV:L3G+
IMR32	NVzBWoV4S3m2b4TvfIlkKEG\|c3H5	NVz0fmpkOTBizszN	NILXUWo4OiCq	NHq2UYdFVVOR	MX7JR\|UxRTBwMEOg{txO	NFfndWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[2PVM{PSd-MkK2Olk{OzV:L3G+
Molt-4	NEP1T41EgXSxdH;4bYMhSXO\|YYm=	MkLUNVAh\|ryP	NYHMVHd2PzJiaB?=	MWDEUXNQ	MoTuTWM2OD1yLkCyJO69VQ>?	M3PQOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nk[5N\|M2Lz5{Mk[2PVM{PTxxYU6=
MOLM-13	NVLnRWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3L6bVMh\|ryP	NHTUUpY4OiCq		MXrEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	NFe3epI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
HL-60	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;JTFMh\|ryP	Ml7hO\|IhcA>?		MYrEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	M2HmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
MV4-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3KyR\|Mh\|ryP	M4j3WVczKGh?		NF\tWXJFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	Mn\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
SKM-1	M{myZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2T4TVMh\|ryP	NVPsZotmPzJiaB?=		NEOyUWhFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NGnBdlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
SH2	MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33UN\|Mh\|ryP	NVj5U3RRPzJiaB?=		NUiyNHU5TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NUC0UVFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
NOMO-1	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\BboFROyEQvF2=	MoHXO\|IhcA>?		MWfEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	NXzmdXQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
OCL-AML2	NHrtd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnWbFZqOyEQvF2=	NGDBb4g4OiCq		NF;oWVRFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NYWzS3Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
PL-21	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDsWHBoOyEQvF2=	MojXO\|IhcA>?		M3PhV2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NF3zcWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
KG-1	NFXvW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUG5[483OyEQvF2=	MYm3NkBp		NETpNW5FcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NHrLVmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
A172	NUDO[FR7S3m2b4TvfIlkKEG\|c3H5	NVLXU2hOOTByIN88US=>	MlnmNlQhcA>?	MnnXSG1UVw>?	NYnHNVdlUUN3ME2wMlEzOCEQvF2=	M3W5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
U87	NEWzNoJEgXSxdH;4bYMhSXO\|YYm=	M3Wy[lExOCEQvF2=	MmLHNlQhcA>?	MnrwSG1UVw>?	MVXJR\|UxRTBwMUC1JO69VQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
U251	M175OWN6fG:2b4jpZ{BCe3OjeR?=	NGrieVkyODBizszN	NXXEXIo3OjRiaB?=	NF3Edm9FVVOR	Mo\FTWM2OD1yLkGwNEDPxE1?	NIHIcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
T98	M3f6WGN6fG:2b4jpZ{BCe3OjeR?=	NGrneVAyODBizszN	M4C1[lI1KGh?	M3PxNGROW09?	NF73OnhKSzVyPUCuNVI2KM7:TR?=	NYPjd4lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
LN18	NH3VVHBEgXSxdH;4bYMhSXO\|YYm=	M{C5TVExOCEQvF2=	M4TlUFI1KGh?	NFW2WotFVVOR	NF\tbWtKSzVyPUCuNlExKM7:TR?=	NUO3TnE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
LN443	MmHsR5l1d3SxeHnjJGF{e2G7	Mo\kNVAxKM7:TR?=	MkfaNlQhcA>?	NEXvToNFVVOR	MlTYTWM2OD1yLkKyNEDPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
HF66	M1jGSmN6fG:2b4jpZ{BCe3OjeR?=	MkPlNVAxKM7:TR?=	M1nHNlI1KGh?	Mke1SG1UVw>?	NEjaW5NKSzVyPUCuNlI2KM7:TR?=	NFfh[XE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
HF2303	NXnmcnJ6S3m2b4TvfIlkKEG\|c3H5	M{nzVFExOCEQvF2=	NF;OVoYzPCCq	NV3TU5NSTE2VTx?=	NGq5TplKSzVyPUCuNFYxKM7:TR?=	NHX4PII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
HF2359	MV\DfZRwfG:6aXOgRZN{[Xl?	M3ixOlExOCEQvF2=	NG\mSo0zPCCq	M3TPV2ROW09?	NYqwcYxlUUN3ME2wMlA3OCEQvF2=	MmTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF2414	NXvWOJpjS3m2b4TvfIlkKEG\|c3H5	NV7UZXJ[OTByIN88US=>	NYfDS2xLOjRiaB?=	NHr5cW5FVVOR	M4j3c2lEPTB;MD6wPFAh\|ryP	NE[4T409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
A-673	NXzWe2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nHdVExKM7:TR?=	M2XyUlk3KGh?	NX3QR4NLTE2VTx?=	M{nu[GlEPTB;MD6wN\|Ih\|ryP	NEPRSI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
TC-32	NUHNN2loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfT[nJoOTBizszN	MmDXPVYhcA>?	NHHCUHRFVVOR	NUHZfo9RUUN3ME2wMlA{QSEQvF2=	Mnn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
TC-71	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVexNEDPxE1?	MmfmPVYhcA>?	M3X3RWROW09?	M4e5U2lEPTB;MD6xNFIh\|ryP	MnLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SK-N-MC	NWjnbnJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7iNVAh\|ryP	MnOwPVYhcA>?	M4XxXWROW09?	MVHJR\|UxRTBwMEeyJO69VQ>?	NWe3XplvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-9	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuxNEDPxE1?	NX7hTpFSQTZiaB?=	M3LkfWROW09?	MkPTTWM2OD1yLkCxPEDPxE1?	MlX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-10	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET5fGYyOCEQvF2=	MYC5OkBp	NYe4NIJ{TE2VTx?=	NYGwR\|Z[UUN3ME2wMlA3OCEQvF2=	M3j6[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-25	MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjWNVAh\|ryP	MV65OkBp	M4H1bWROW09?	M1HTemlEPTB;MD6xOlgh\|ryP	NGLmfXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-32	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TqZVExKM7:TR?=	M4TOSVk3KGh?	NYXreFYzTE2VTx?=	NVTWSYgxUUN3ME2wMlE{PiEQvF2=	NXXU[3A{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-56	NFHp[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUKxNEDPxE1?	MYq5OkBp	MXHEUXNQ	Moe3TWM2OD1zMDFOwG0>	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-258	NF76bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxNEDPxE1?	M2\oVFk3KGh?	Mnu5SG1UVw>?	NVu2O5JNUUN3ME2wMlE{OiEQvF2=	M2fxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
COG-E-352	M4XqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfZNVAh\|ryP	Mn\uPVYhcA>?	MlrrSG1UVw>?	M13USGlEPTB;MD6wOFMh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-90	NFTkPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV60XGlyOTBizszN	NU\1OoRsQTZiaB?=	NEjwWotFVVOR	M4HvR2lEPTB;MD6wOlEh\|ryP	NXu0fVFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-119	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXGclhkOTBizszN	NYfBWnZtQTZiaB?=	NWKwcI5TTE2VTx?=	Ml;3TWM2OD1yLkCyNkDPxE1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-122	M3vpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP5ZlEyOCEQvF2=	MWq5OkBp	MYjEUXNQ	NFu3bVBKSzVyPUCuNFE6KM7:TR?=	NHzJdGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-136	M4fCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjqToMyOCEQvF2=	NWjIXm9WQTZiaB?=	MVnEUXNQ	NFHVSVBKSzVyPUCuNFM6KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-140	NF7EXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKzdZoyOCEQvF2=	MYO5OkBp	NHrKZmpFVVOR	MorlTWM2OD1yLkCyOkDPxE1?	NX;LfnNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
LA-N-6	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jjSVExKM7:TR?=	MnHnPVYhcA>?	MUPEUXNQ	M1HKSWlEPTB;MD6wOVQh\|ryP	Mnj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
NB-1643	NVnP[GZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[xWFExKM7:TR?=	M13XU\|k3KGh?	MX3EUXNQ	NH32dFRKSzVyPUCuNFM4KM7:TR?=	M{O2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
NB-EBc1	M{nK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:2PGsyOCEQvF2=	MmDKPVYhcA>?	MmP1SG1UVw>?	M4nEe2lEPTB;MD6wOVAh\|ryP	NVPRUmFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SK-N-BE-1	M2DSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHENVAh\|ryP	NILQVWU6PiCq	MYHEUXNQ	MkHOTWM2OD1yLkCyPEDPxE1?	NUTLZ5VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SK-N-BE-2	NVTyVFNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfUPIhqOTBizszN	M3fMPFk3KGh?	Ml3VSG1UVw>?	NYfqVVJJUUN3ME2wMlA{PiEQvF2=	NUCyVVMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KAN	NEnXS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT5SIZZOTBizszN	MYG5OkBp	NWfpXG5tTE2VTx?=	NHjxRVNKSzVyPUCuNFM1KM7:TR?=	NYPJcWlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KANR	M4rxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOxNEDPxE1?	NH3vbG06PiCq	MV;EUXNQ	NFrZZm9KSzVyPUCuNFI3KM7:TR?=	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-KCN	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHRNVAh\|ryP	MmftPVYhcA>?	M1HVe2ROW09?	M{fIemlEPTB;MD6wNVkh\|ryP	NFe4Voo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KCNR	NILpNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrzNVAh\|ryP	M{nyV\|k3KGh?	NFjHWm5FVVOR	NGTaS5lKSzVyPUCuNFExKM7:TR?=	NUPxenRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-LHN	NHzFXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvQ[5pvOTBizszN	NXu1OpFyQTZiaB?=	MnTOSG1UVw>?	M3G5OmlEPTB;MD6wN\|Ih\|ryP	NEiwb\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-MSN	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxNEDPxE1?	M4Cxb\|k3KGh?	MoXUSG1UVw>?	M3X3XGlEPTB;MD6wNlIh\|ryP	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-SAN	M2S2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnOZ3lvOTBizszN	MmP5PVYhcA>?	MoLNSG1UVw>?	MkPvTWM2OD1yLkCyNEDPxE1?	NXrVW21iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
Granta-4	Ml\kR5l1d3SxeHnjJGF{e2G7	MU[xNEDPxE1?	MXO3JIQ>		NVPHeWd1UUN3ME2wMlA1OCEQvF2=	NUXIS4NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVE5PjdpPkKxNlkyQDZ5PD;hQi=>
DB	Mn;WR5l1d3SxeHnjJGF{e2G7	MU[xNEDPxE1?	MoiyO{Bl		MYLJR\|UxRTBwMESyJO69VQ>?	MnmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUG4OlcoRjJzMkmxPFY4RC:jPh?=
RL	MmHqR5l1d3SxeHnjJGF{e2G7	MVSxNEDPxE1?	MU[3JIQ>		NFjpRmNKSzVyPUCuNFE2KM7:TR?=	M2DoNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmxPFY4Lz5{MUK5NVg3PzxxYU6=
K562	M4TPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf2U\|QyOCEQvF2=	MYC5OkBp		MoXzTWM2OD1yLkC4O{DPxE1?	MlXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOUG2N\|MoRjJzMEmxOlM{RC:jPh?=
LAMA-84	NXPs[4JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDLNVAh\|ryP	MVW5OkBp		NXHsZmhEUUN3ME2wMlA2PyEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB7MU[zN{c,OjFyOUG2N\|M9N2F-
MM15	M3T6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPHOEDPxE1?	NHfBT3k4OiCq	MYTEUXNQ	M4TmTmlEPTB;MD6xN{DPxE1?	MlzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
OPM1	NYjQVo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rlPFQh\|ryP	MlfHO\|IhcA>?	NWjSVFl7TE2VTx?=	MkLtTWM2OD1yLkCzJO69VQ>?	M3nVU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
RPM1	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWC0JO69VQ>?	MU[3NkBp	NWXScIJyTE2VTx?=	Mo\uTWM2OD1zMD6zNkDPxE1?	NHjZNZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO4Nlg1PCd-MkCzPFI5PDR:L3G+
INA6	NWnTfYpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUG0JO69VQ>?	Mn7YO\|IhcA>?	NV3sRo9pTE2VTx?=	M3vsZ2lEPTB;MD6wNFIh\|ryP	NXXscIZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
OPM2	MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3EOEDPxE1?	Ml:2O\|IhcA>?	MoXhSG1UVw>?	NXTTOlF3UUN3ME20MlM4KM7:TR?=	NYfW[otQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
MM1R	MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\abJZFPCEQvF2=	M4rYZVczKGh?	NHnwenVFVVOR	MlvNTWM2OD1zLk[4JO69VQ>?	NX:0TZdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
DOX40	NYnPOZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jselQh\|ryP	M1vTVlczKGh?	NWPNRo01TE2VTx?=	NFXTWopKSzVyPUWuOFgh\|ryP	M{OxSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
LR5	M{XqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjrclNRPCEQvF2=	MnTlO\|IhcA>?	M33IOmROW09?	MmLnTWM2OD1{LkWzJO69VQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
U266	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH74RZY1KM7:TR?=	NXiwZmgyPzJiaB?=	NVu2NGZ6TE2VTx?=	M{O3SmlEPTB;MT60N{DPxE1?	NGT5Xlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO4Nlg1PCd-MkCzPFI5PDR:L3G+
RD	M{O3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	MnewPVYhcA>?		M2\xSGlEPTB;MD6yNlgh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Rh41	M2PUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfDNVAh\|ryP	M4X0cFk3KGh?		NXvzSYJuUUN3ME2wMlA6OCEQvF2=	M{P2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Rh30	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6xNEDPxE1?	NFTyb2M6PiCq		NHXkZ\|NKSzVyPUCuNlMxKM7:TR?=	MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
BT-12	NXr5Oo41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;FSowyOCEQvF2=	NYfZeo9WQTZiaB?=		M4fzO2lEPTB;MD6wOlAh\|ryP	NXfsNYh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
CHLA-266	NEPH[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vIZ\|ExKM7:TR?=	M4Lxd\|k3KGh?		MVfJR\|UxRTBwMEeyJO69VQ>?	Mlm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
TC-71	NFnJTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LUflExKM7:TR?=	NIDzXYY6PiCq		M2THVmlEPTB;MD6xNFIh\|ryP	M3jyeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
SJ-GBM2	NY\DU2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGD4TZkyOCEQvF2=	NHzIR3A6PiCq		MljDTWM2OD1yLkC1NEDPxE1?	MkjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
NALM-6	NYfGU2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\xOVExKM7:TR?=	NYfMXZlLQTZiaB?=		M4T3VGlEPTB;MD6wOlIh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
COG-LL-317	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNEDPxE1?	M2fLcVk3KGh?		NFy0U29KSzVyPUCuNFQ4KM7:TR?=	NF36WoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
RS4-11	NF3OXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXyxNEDPxE1?	MkSzPVYhcA>?		MVXJR\|UxRTBwMEG4JO69VQ>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
MOLT-4	NUjEZoozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWixNEDPxE1?	MmfqPVYhcA>?		NFi3XFdKSzVyPUCuNFI3KM7:TR?=	MlzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
CCRF-CEM	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTUV3pLOTBizszN	NWHOWXd4QTZiaB?=		MVLJR\|UxRTBwMEm0JO69VQ>?	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
Kasumi-1	NWmwNVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXkd4cyOCEQvF2=	M{LZZlk3KGh?		M1vYcmlEPTB;MD6xNFMh\|ryP	M1fGSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Karpas-299	NETlXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fBSlExKM7:TR?=	NGjUO486PiCq		NU\LVIU5UUN3ME2wMlA{QCEQvF2=	NXf2e\|lVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Ramos-RA1	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETZUlkyOCEQvF2=	M3v3bFk3KGh?		NX\NNlh3UUN3ME2wMlEzPyEQvF2=	M3P2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
GSS	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1zrdlczKGi{cx?=		MnfoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCJU2OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkCzPUDPxE1w	MnTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
LU99A	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmmzO\|IhcHK\|		MkfXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOVUm5RUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFYzKM7:TT6=	NW\0dJMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HL60	NUnqfmVkSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUfEO4pzPzJiaILz		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkC3OEDPxE1w	MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
LC2/ad	MmTLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NX;xNWU2PzJiaILz		M1Xpc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTFOyM4FlKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4xPzdizszNMi=>	M3jSV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
MKN45	M1Hqd2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{DYU\|czKGi{cx?=		MnHZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPS160OUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk{KM7:TT6=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
HCT116	M4i0W2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NF\FPI84OiCqcoO=		NYq0UZJ[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjB7NTFOwG0v	NIG4PYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
Lu116	M4fwOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NI\mXFc4OiCqcoO=		MkjBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOdUGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk4KM7:TT6=	NVq0ZZhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
NCI-H358	NFzQWFVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGKzeJg4OiCqcoO=		NXv5PG5FSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDN3ODDj[YxteyCjZoTldkA4OiCqcoOgZpkhX1OWODDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	NWn1[HFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
MIAPaCa2	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NI\hfVg4OiCqcoO=		M3X3eWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjF\|IN88UU4>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
PC14	M{LqRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWXwdIZLPzJiaILz		M3rSe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOxOEBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNVch\|ryPLh?=	NYP5T49vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HT-29	M4Lk[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{np[\|czKGi{cx?=		MlnORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuN\|Mh\|ryPLh?=	M4HocVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
HCT15	M2Pyb2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVS3NkBpenN?		MoL6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
Sf9	M2XEU2Z2dmO2aX;uJIF{e2G7				M4q2fWNwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gdoVkd22kaX7hcpQhdW:3c3WgZZVzd3KjIHvpcoF{\SCDIHX4dJJme3OnZDDpckBqdnOnY4SgV4Y6KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIFHUVEwhU2liPTCwMlAxODNizszNMi=>	MnTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEG1OlQoRjJ4MUCxOVY1RC:jPh?=
Sf9	NYDhV4g1TnWwY4Tpc44h[XO\|YYm=				MWTJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IH3veZNmKGG3cn;yZUBscW6jc3WgRUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoOTDj[YxteyC3c3nu[{BjcW:2aX6tS2xTWkGVTFegZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYT2zN3BeSVSSLDDJR\|UxKD1iMD6wNFEh\|ryPLh?=	Mn;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEG1OlQoRjJ4MUCxOVY1RC:jPh?=
HCT116	M{nkS2Z2dmO2aX;uJIF{e2G7				M1jUeGlvcGmkaYTpc44hd2ZiYYXyc5JiKGurbnHz[UBCKGG3dH;wbI9{eGixconsZZRqd25iYYSgWFI5QCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMEeg{txONg>?	NVfZOoc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
HCT116	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=				MnLLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGK7IFLy[HUhcW6lb4Lwc5JifGmxbjDhd5NigSxiR1m1NEA:KDBwMEOg{txONg>?	NV3TVFN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
HCT116	MWLGeY5kfGmxbjDhd5NigQ>?				M2\3d2lvcGmkaYTpc44hd2ZiYYXyc5JiKGurbnHz[UBDKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHjpd5RwdmViSEOgdIhwe3Cqb4L5cIF1cW:wIHL5JIludXWwb3\seY9z\XOlZX7j[UBidmGueYPpd{whUUN3MDC9JFEvPSEQvF2u	MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEG1OlQoRjJ4MUCxOVY1RC:jPh?=
BL21 (DE3) Rosetta	NXvv[25ITnWwY4Tpc44h[XO\|YYm=		NEfKOms{OCCvaX7z		Moe0TY5pcWKrdHnvckBw\iCKaYOteIFo\2WmIHj1cYFvKEG3cn;yZUBCKGurbnHz[UApOTJ{IITvJFQxKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJHJwe2W2dHGgZ4VtdHNidYPpcoch[mmxdHnufYxifGWmIGPUT\|Ihe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgN\|AhdWmwczDifUBJXFKIIHHzd4F6NCCLQ{WwJF0hOC5yMECwOEDPxE1w	NVywb4ZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVEyOzNpPkK3N\|kyOTN\|PD;hQi=>
HeLa Kyoto	MkjSSpVv[3Srb36gZZN{[Xl?		NWfxOJZqOjBiaILz		NXP2ZpZXUW6qaXLpeIlwdiCxZjDBeZJwemFiQjDrbY5ie2ViaX6gbJVu[W5iSHXMZUBMgW:2bzDj[YxteyCjc4Pld5Nm\CCjczDl[oZm[3Rib36g[Il{fHKrYoX0bY9vKG:oIIDod5Bpdy2qaYP0c45mKEh\|IIPldlExKGyndnXsJIlv[3WkYYTl[EBnd3JiMkCgbJJ{NCCLQ{WwJF0hOC5yMEG1JO69VS5?	NHT5[mI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5NVE{Oyd-MkezPVEyOzN:L3G+
HeLa Kyoto	NGXrZZVHfW6ldHnvckBie3OjeR?=		NFHsWIczOCCqcoO=		NXLOd4pMUW6qaXLpeIlwdiCxZjDBeZJwemFiQTDrbY5ie2ViYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBVcHJ{OEigbY4hcHWvYX6gTIVN[SCNeX;0c{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDJyIHjyd{whUUN3MDC9JFAvODB4NzFOwG0v	MorGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OUGxN\|MoRjJ5M{mxNVM{RC:jPh?=
multiple myeloma	M3zEPGZ2dmO2aX;uJIF{e2G7				MVvTeZBxemW\|c3nvckBw\iClZXzsJI1qfG:\|aYOgbY4hcHWvYX6gcZVtfGmybHWgcZlmdG:vYTDj[YxteyxiSVO1NEA:KDBwMECzJO69VS5?	MoPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7MUiwPVYoRjJ6OUG4NFk3RC:jPh?=
Calu6	M4H1T2FvfGm2dX3vdkBie3OjeR?=	NGXXepQzOCCvZz;r[y=>	NEPtT\|AzOSCmYYnz		MWDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFYXz1OkBk\WyuczD4[Y5w\3KjZoTl[EBqdiCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB{MDDt[{9s\yxicH:gZollKGGmbXnubZN1\XKnZDDmc5IhOjFiZHH5dy=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMUW2OEc,OjZzMEG1OlQ9N2F-
HeLa Kyoto	NVLifWVETnWwY4Tpc44h[XO\|YYm=	M2S2SFAvOjVidV2=	NEnPd3IzOCCqcoO=		MkjSTY5pcWKrdHnvckBw\iCDdYLvdoEhSSCtaX7hd4UhdG:lYXzpfoF1cW:wIHH0JJNxcW6mbHWgcYlkem:2dXL1cIV{KGmwIHj1cYFvKEinTHGgT5lwfG9iY3XscJMh[XRiMD6yOUB2VSCrbnP1ZoF1\WRiZn;yJFIxKGi{cx?=	M1HGSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{mxNVM{Lz5{N{O5NVE{OzxxYU6=
MDA-MB-231	NH3YNYdHfW6ldHnvckBie3OjeR?=	NWLBc3FqOSC3TR?=	M3PPUVQ5KGi{cx?=		MUDJcoR2[3Srb36gc4Yh[2i{b33vd49u\SCjbHnnco1mdnRiZHXm[YN1eyCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JGRCWElic4ThbY5qdmdiYnHz[YQhcW2vdX7v[ox2d3Knc3PlcoNmKGG\|c3H5	MnnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	M2TPR2Z2dmO2aX;uJIF{e2G7	MUSxJJVO	M3zNdlQ5KGi{cx?=		NV:0S2wxUW6mdXP0bY9vKG:oIHHi[ZJz[W62IIPwbY5ldGViZn;ycYF1cW:wIIfpeIghfHKrcH;sZZIh[W6mIITleJJieG:uYYKgc4NkfXK{ZX7j[UBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG\|ZXSgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7	MnjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	NYXJdlQ{TnWwY4Tpc44h[XO\|YYm=	NXzCWVlxOC53IIXN	MmTKOFghcHK\|		NVXKUY5XUW6qaXLpeIlwdiCxZjDhcJBp[S22dXL1cIlvKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiYXLvcIl{cG2nboSgc4YhemWpdXzhdkBtd2OjdHnvckBw\iCycn;0[YlvKGG2IECuOUB2VSCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCrbX31co9ndHWxcnXzZ4Vv[2ViYYPzZZk>	MofnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	M{f3b2Z2dmO2aX;uJIF{e2G7	NHfJ[3kxNjVidV2=	M331fFQ5KGi{cx?=		NIPOWVlKdmirYnn0bY9vKG:oIFHVVmtCKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiYXLvcIl{cG2nboSgc4YhemWpdXzhdkBtd2OjdHnvckBw\iCycn;0[YlvKGG2IECuOUB2VSCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCrbX31co9ndHWxcnXzZ4Vv[2ViYYPzZZk>	NYK4VXhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzOVgyPDdpPkK5N\|U5OTR5PD;hQi=>
TC32	NGGxWWtyUFSVIHHzd4F6				NYrrTZZDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIO=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MYDxTHRUKGG\|c3H5				NHjpXZJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NFrGVnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	M4\D[JFJXFNiYYPzZZk>				M{PmTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NI\Ud209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MmHCdWhVWyCjc4PhfS=>				NVnpW5ZCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	M1f1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MV3xTHRUKGG\|c3H5				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	M2H1fpFJXFNiYYPzZZk>				MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	M3L2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NFvyR\|RyUFSVIHHzd4F6				NH3MeVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	MlvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NXe2[FlPeUiWUzDhd5NigQ>?				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	NIDXS249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NF7JN2ZyUFSVIHHzd4F6				M2rkW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NY\4SZl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MkLDdWhVWyCjc4PhfS=>				MmLzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	Mo\kdWhVWyCjc4PhfS=>				MnvidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M{PNbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NV7zTW1LeUiWUzDhd5NigQ>?				NGnuPGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	M1nObVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MmW5dWhVWyCjc4PhfS=>				MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	Mm\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MV7xTHRUKGG\|c3H5				NWiyeGFweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NX:3UJV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	M4DKTZFJXFNiYYPzZZk>				M{DaNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NXnRUWtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NYTF[Fg4eUiWUzDhd5NigQ>?				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM>	M4jONVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

In vivo

MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-³³P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:^[2]	- Collapse Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24, 48, and 72 hours Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using ³[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells Dosages: ~30 mg/kg/day Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+30% PEG300+5%Tween-80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Alisertib (MLN8237) SDF

Molecular Weight	518.92
Formula	C₂₇H₂₀ClFN₄O₄
CAS No.	1028486-01-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04479306	Recruiting	Drug: Alisertib\|Drug: Osimertinib\|Drug: Sapanisertib	Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center	June 18 2020	Phase 1
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Completed	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the suggested formulation of this compound for mouse injection(i.p.)?
Answer:
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitor

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitor

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
ML141 ^New

ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.
Salirasib ^New

Salirasib (Farnesylthiosalicylic acid, FTS) is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with K_i of 2.6 μM, which inhibits _Ras methylation. Salirasib exerts antitumor effects and induces autophagy. Salirasib exerts antitumor effects and induces autophagy. Phase 2.
Barasertib (AZD1152-HQPA)

Barasertib (AZD1152-HQPA, AZD2811, INH-34) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Tozasertib (VX-680, MK-0457)

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and BCR-ABL tyrosine kinase, which are inhibited by the Tozasertib with both Ki of 30 nM. Tozasertib induces apoptosis and autophagy. Phase 2.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Danusertib induces apoptosis, cell cycle arrest, and autophagy. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. MK-5108 (VX-689) induces autophagy. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I (TC-S 7010) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B. Aurora A Inhibitor I (TC-S 7010) triggers apoptosis through the ROS-mediated UPR signaling pathway.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)